Who is sponsoring NCT04487197?

NCT04487197 is sponsored by Antonio Secchi.

What drugs are being tested in NCT04487197?

Interventions in NCT04487197: blood sample for seroepidemiological investigation.

What condition does NCT04487197 study?

NCT04487197 studies Kidney Transplant, Pancreatic Transplat, Pancreatic Islets Langerhans.

Is NCT04487197 still recruiting?

NCT04487197 is currently completed. Last updated 10 February 2021.

Last reviewed 2021-02-10 · How we verify

NCT04487197

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SARS-CoV2 (COVID-19) Seroepidemiological Transplanted Subjects (Kidney, Kidney-pancreas, Pancreas, Langerhans Islets)

Completed Last updated 10 February 2021

What this trial tests

trial testing blood sample for seroepidemiological investigation in Kidney Transplant in 282 participants. Completed in 15 January 2021.

Timeline

15 July 2020

Primary endpoint
15 January 2021

15 January 2021

Quick facts

Lead sponsor	Antonio Secchi
Status	Completed
Study type	OBSERVATIONAL
Enrollment	282
Start date	15 July 2020
Primary completion	15 January 2021
Estimated completion	15 January 2021
Sites	1 location across Italy

Drugs / interventions tested

blood sample for seroepidemiological investigation

Conditions studied

Kidney Transplant — all drugs for Kidney Transplant →
Pancreatic Transplat — all drugs for Pancreatic Transplat →
Pancreatic Islets Langerhans — all drugs for Pancreatic Islets Langerhans →

Sponsor

Antonio Secchi

Who can join

18 and older, any sex, with Kidney Transplant or Pancreatic Transplat. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate SARS-CoV2 infection and the degree of immunity possibly developed in transplanted population using the Luciferase Immuno Precipitation System (LIPS) test.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

COVID-19 in Solid Organ Transplant Recipient: Exploring Cumulative Incidence, Seroprevalence and Risk Factors for Disease Severity.
Caldara R, Maffi P, Costa S, Bazzigaluppi E, et al · · 2021 · cited 2× · PMID 34943264 · DOI 10.3390/biology10121349

Verify or expand the search:

Other recruiting trials for Kidney Transplant

Currently open trials in the same condition.

NCT07532382 — Personalized Stories for Pediatric Kidney Recipients · recruiting
NCT07348458 — Kidney Protective Jacket · NA · recruiting
NCT07333495 — A Mixed Cohort, Multicentre Exploratory Study of Non-invasive Quantitative Assessment of Renal Graft Function With Non-c · recruiting
NCT06919003 — Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE · Phase 2 · recruiting
NCT07205692 — Multimorbidity and Cardiovascular Risk Factors After Renal Transplant · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04487197 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Antonio Secchi
Last refreshed: 10 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04487197.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing